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background: Hormonal effects of soy and isoﬂavones have been investigated in numerous trials with equivocal ﬁndings. We aimed to
systematically assess the effects of soy and isoﬂavones on circulating estrogen and other hormones in pre- and post-menopausal women.
methods: The Cochrane Library, MEDLINE and EMBASE (plus reviews and experts) were searched to December 2007. Inclusion of
randomized or residential crossover trials of soy or isoﬂavones for 4 or more weeks on estrogens, SHBG, FSH, LH, progesterone and
thyroid hormones in women was assessed independently in duplicate. Six percent of papers assessed were included. Data concerning
participants, interventions, outcomes, potential effect modiﬁers and trial quality characteristics were extracted independently in duplicate.
results: Forty-seven studies (11 of pre-, 35 of post- and 1 of perimenopausal women) were included. In premenopausal women, meta-
analysis suggested that soy or isoﬂavone consumption did not affect primary outcomes estradiol, estrone or SHBG concentrations, but sig-
niﬁcantly reduced secondary outcomes FSH and LH [by 20% using standardized mean difference (SMD), P ¼ 0.01 and 0.05, respectively].
Menstrual cycle length was increased by 1.05 days (95% CI 0.13, 1.97, 10 studies). In post-menopausal women, there were no statistically
signiﬁcant effects on estradiol, estrone, SHBG, FSH or LH, although there was a small statistically non-signiﬁcant increase in total estradiol
with soy or isoﬂavones (14%, SMD, P ¼ 0.07, 21 studies).
conclusions: Isoﬂavone-rich soy products decrease FSH and LH in premenopausal women and may increase estradiol in post-
menopausal women. The clinical implications of these modest hormonal changes remain to be determined.
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Although interest in the relative importance of isoﬂavones to human
health has increased over the last 15 years, their effects on health
are not clearly established. Isoﬂavones are diphenolic compounds
with a range of characterized biological effects from in vitro studies.
To date much of the interest in their biologic activity relates to estro-
gen receptor-mediated mechanisms, given their structural similarity to
estrogens (Axelson et al., 1984; Kuiper et al., 1998; Gallo et al., 2005;
Hwang et al., 2006; Messina, 2007), but numerous other biological
effects independent of estrogen receptors have also been determined
[e.g. antioxidant capacity, antiproliferative and anti-inﬂammatory
effects (Kuiper et al., 1998; Setchell and Cassidy, 1999; Gallo et al.,
2005; Hwang et al., 2006; Messina, 2007)].
Following modest soy consumption, typical for East Asians, circulat-
ing isoﬂavone concentrations reach the low micromolar level, 100–
1000 times that of endogenous estrogen levels, although they circulate
predominantly in the less biologically active conjugated form (Axelson
et al., 1984; Adlercreutz and Mazur, 1997). These compounds may
affect estrogen action by directly binding to estrogen receptors, pre-
ferentially estrogen receptor b, thus potentially directly affecting tran-
scription of estrogen-regulated gene products (Kuiper et al., 1997; Pike
et al., 1999; An et al., 2001; Lacey et al., 2005; Hwang et al., 2006),
acting as estrogen agonists in some contexts and estrogen antagonists
in others, much like the selective estrogen receptor modulators
tamoxifen or raloxifene. Isoﬂavones may also inﬂuence estrogen
action by virtue of effects on enzymes involved in steroid metabolism,
including aromatase (Rice et al., 2006), 17b-hydroxysteroid dehydro-
genases, steroid sulfatases and sulfotransferases (Lacey et al., 2005),
potentially resulting in alterations of circulating estrogens.
Data from human clinical trials evaluating possible beneﬁcial effects
of isoﬂavone-rich products on a variety of health outcomes have been
mixed—e.g. some studies suggest that isoﬂavones inhibit bone loss or
alleviate hot ﬂushes (Howes et al., 2006; Williamson-Hughes et al.,
2006; Marini et al., 2007; Ma et al., 2008), whereas others have
observed no effect (Balk et al., 2005; Nelson et al., 2006; Sacks
et al., 2006). Although evidence on health effects in humans is deba-
table, endocrine modulation in several animal species has been
reported following exposure to high levels of isoﬂavones from soy
and red clover (Bennetts et al., 1946; Setchell et al., 1987; Adams,
1995). These hormonal effects in animals have raised questions
about the safety of soyfoods (the main source of isoﬂavones in the
human diet), despite a long history of soyfood consumption by
many East Asian populations (Messina et al., 2006b).
There are a number of possible explanations for the variability in
results among soy studies. A wide variety of intervention products
with markedly varying isoﬂavone content have been used, including
traditional soyfoods, isolated soy protein (ISP), soy extracts and iso-
lated isoﬂavones, each with a variety of controls (Erdman et al.,
2004). Other variables include amounts of protein in products, meno-
pausal status of the participants, stage of menstrual cycle in premeno-
pausal women and degree to which dietary intake is controlled.
A systematic evaluation of the literature, ensuring inclusion of the
entire set of relevant studies, with greater statistical power to
examine the effects of isoﬂavone-containing soy products on hormonal
status, provides improved potential to examine the hormonal effects of
soy isoﬂavones in women. We therefore conducted such a systematic
review, and meta-analysis, of the literature to examine the effects of
isoﬂavone-containing soy products on circulating levels of estrogens
and other hormones in pre- and post-menopausal women.
Methods
Included studies were required to: be randomized trials or carefully con-
trolled intervention studies (the former had to state that they were ran-
domized or explicitly describe a true randomization method, the latter
had to be residential crossover studies that provided and monitored all
food and drink intake); be parallel or crossover in design; have an interven-
tion duration  4 weeks; be in women  16 years old (pre- or post-
menopausal, not critically ill, pregnant or breastfeeding); increase intake
of soy, soy products or puriﬁed soy isoﬂavones compared with usual diet
or usual diet with placebo soy/isoﬂavone; be unifactorial (so that effects
of soy or isoﬂavones could be separated from those of other interventions);
and assess at least one primary or secondary review outcome. Primary out-
comes were circulating estradiol, estrone and SHBG in pre- and post-
menopausal women. Secondary outcomes were FSH, LH, progesterone,
circulating estrone sulfate, circulating free estradiol, thyroid hormones (T4,
T3 or TSH), urinary estrogens and estrogenic metabolites, menstrual
cycle length, luteal and follicular phase lengths, and IGF-1.
Structured electronic searches were carried out on The Cochrane
Library, MEDLINE, EMBASE and the Meta-register of controlled trials
(http://www.controlled-trials.com/mrct/), from inception to December
2007, in the format: [soy or isoﬂavones] AND [hormones] AND [ran-
domized controlled trials]. We also checked the reference lists of large
non-systematic reviews of trials of soy and isoﬂavone to ensure studies
assessing hormones as secondary outcomes were not missed. Experts
were contacted to obtain further (and unpublished) trials. Studies were
not limited by publication status (whether fully published, published in
abstract form, or unpublished) or language of publication.
Resulting titles and abstracts were assessed independently in duplicate
by two reviewers and full text articles collected. Inclusion was assessed
independently in duplicate by two reviewers, and disagreements resolved
by discussion. Included papers were grouped into studies and data (on
participants, interventions, outcomes at the latest time point to 53
weeks, trial quality characteristics and potential effect modiﬁers) were
extracted independently by two reviewers onto a data extraction form
reﬁned by the entire review team.
Trial quality characteristics assessed included: masking (separately) of
participants and outcome assessors (coded as ‘yes’ where there was a
clear and realistic attempt to mask, ‘no’ where not, or ‘unclear’—
success of masking was rarely checked in included studies); industry
funding or involvement (any funding, including full funding of the study,
co-authorship of a scientist or statistician working for industry or provision
of materials to be used during the intervention and/or control, and coded
as ‘yes, industry funding’, ‘none reported’ or ‘unclear’); duration (coded as
‘done’ for all post-menopausal studies of at least 4 weeks in duration, and
premenopausal studies of at least 3 cycles duration or ‘not done’ for
shorter premenopausal studies); assessment and reporting of compliance
(‘done’ when compliance was both assessed and reported, ‘partly done’
when it was assessed but not reported or reported without any indication
of the method used, and ‘not done’ when neither was addressed ade-
quately); isoﬂavone content (reported as ‘done’ when total isoﬂavone,
genistein and daidzein contents reported in both intervention and
control, aglycone or glycated form reported, ‘partially done’ when at
some of the above completed, ‘not done’ when not); isoﬂavones analyzed
(‘done’ when the intervention dose was checked and reported, or
‘unclear’ if not carried out or not reported); and dropouts [reported as
‘done’ when the numbers of participants who were randomized,
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outs were given (by intervention arm), ‘partially done’ when some of the
above, ‘not done’ when none of these data were presented]. Trials were
considered to be at low risk of bias if participant and outcome assessor
blinding were all coded ‘yes’, industry funding was not reported, duration
was done and dropouts ‘done’. All other trials were considered at
moderate or high risk of bias.
For premenopausal studies, it was not feasible to choose any single phase
of the menstrual cycle for data extraction (i.e. data were measured at differ-
ent points during the cycle and selection of day of sampling within phase
varied). Thus, we chose the point in each study with the highest control
group baseline measurement for each outcome. This was based on the
premise that it is the level and timing of the peak of hormone concentration
that is important in determining health effects rather than the baseline levels
present at other times of the cycle. This approach, while not ideal, was
based on the premise that this was the point at which any changes due
to soy or isoﬂavones might be most easily detected. To check that this
assumption did not result in missing effects based on the use of non-peak
data, we re-ran the analyses using data from the luteal phase only for estro-
gens, FSH and LH, and the follicular phase for progesterone.
Isoﬂavone dose was calculated in aglycone equivalents (glycoside levels
were multiplied by 0.6). For primary and secondary outcomes, the number
of participants assessed, means and standard deviations of change from
baseline (where available, or data at the end of the intervention and
control periods where change data were not available) in hormonal con-
centration in each treatment arm were extracted. For crossover studies,
we aimed to use within-participant differences with the variance of
these differences (Elbourne et al., 2002); however, the information on var-
iance for the within-participant differences were not provided in our
included studies, and without at least 2 studies providing such data, it
was not possible to impute appropriate variance estimates with any con-
ﬁdence (Follman et al., 1992). For this reason, and because exact P-values
or t-statistics were only available for occasional outcomes in a few of the
crossover studies (generally being reported as ‘signiﬁcant’ or not), mean and
variance for the participants while on each treatment were used instead,
treating results from the intervention period as if they came from one
group of patients and results from the control period as if they came from
a second group of patients. This is not ideal as the two groups are not inde-
pendent (as required for the statistical tests) and will tend to provide a con-
servative estimate of any association as it ignores the within-patient
correlations that give crossover trials their statistical strength (Elbourne
et al., 2002). We ran a sensitivity analysis omitting crossover data except
where an exact t-test or P-value for the relationship between the two
periods was available. Heterogeneity was assessed using I
2 (Higgins et al.,
2003). Data for pre- and post-menopausal women were analyzed separately.
Owing to varied mean baseline hormone concentrations of many hor-
mones (e.g. for post-menopausal women, where menstrual phase was not
relevant, mean total estradiol ranged from ,20 to almost 200 pmol/l at
baseline), we decided that our primary analyses would combine studies
using standardized mean differences (SMD) in random effects
meta-analysis, where at least two studies were combined. This was
because the studies were effectively using different measurement scales
to assess the same effect size. The SMD ‘expresses the size of the inter-
vention effect in each study relative to the variability observed in that
study’ (Anon., 2008; Deeks et al., 2008). Interpretation of the effect
size is problematic as the units are units of standard deviation rather
than the more intuitive pmol/l or equivalent ‘real’ units. For cycle
lengths, studies were combined using mean differences (MD) in random
effects meta-analysis. As a check on our results (sensitivity analysis), we
also ran the meta-analyses using MD in place of SMD, and assessed
robustness of results to trial quality (trials assessed as at moderate or
high risk of bias were removed).
Subgroup analyses explored the effects of the following factors on
the primary outcomes: intake of soy protein (,10, 10–24, 25–49,
50þ g/day of soy protein); isoﬂavone dose (,25 mg/day, 25 to
,50 mg/day, 50 to ,75 mg/day, 75 to ,100 mg/day, 100þ mg/day);
intervention intensity (dietary advice, supplementation or food provided);
equol producers versus non-producers; and isoﬂavone source. We
assessed for evidence of dissemination bias using funnel plots.
Results
Searches identiﬁed 1660 titles and abstracts for assessment (Fig. 1),
217 were retrieved in full text, and 47 studies were included and
data extracted. Details of the included studies are provided in the
appendix.
Eleven included studies were of premenopausal women (579
women analyzed), 35 of post-menopausal women (1165 analyzed),
and 1 of perimenopausal women (69 analyzed). Six studies, all of post-
menopausal women, provided no useable primary or secondary
outcome data, despite requests from authors (data were only pro-
vided as least squares means with associated reduction in standard
errors, did not separate out women using HRT, stated presence or
absence of statistical signiﬁcance but provided no actual data or did
not present variances). However, these studies were included in the
review to help us understand the quantity of missing data, and allow
us to assess the potential of studies not included in the meta-analyses
to alter the results of the pooling (Table I). As outcome reporting may
vary according to whether statistically signiﬁcant effects were seen, we
did not want to assume that studies with missing data would be similar
to those with presented data. Studies ranged in size from 10 to 304
women analyzed (mean 59). Thirty-two included studies were parallel
in design, and 15 crossover. Nineteen studies assessed the effect of
isoﬂavone extract versus control, nine isoﬂavone-containing ISP
versus isoﬂavone-depleted ISP, 13 ISP versus another control, nine
whole soy or soy foods versus control (some studies included more
than one comparison). Studies ranged from 4 to 104 weeks long: 29
were 4–12 weeks in duration; nine were 13–26 weeks; seven 27–
52 weeks; and two .1 year. One was conducted in metabolic
Figure 1 Study ﬂow diagram of the search process and inclusion of
studies into the review.
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Table I Table of primary and secondary outcomes
Premenopausal women Post-menopausal women
No. of studies/
participants
a/
missing
studies
b
SMD (95% CI) I
2 (%)
c MD (95% CI) No. of studies/
participants
a/
missing
studies
b
SMD (95% CI) I
2 (%)
c MD (95% CI)
Primary outcomes
Circulating total E2, pmol/l 11/250/0 20.05 (20.23 to 0.12) 0 27.99 (248.20 to 32.22) 21/580/6 0.13 (20.01 to 0.27) 29.3 2.76 (20.37 to 5.90)
Circulating total E1, pmol/l 6/207/1 20.09 (20.29 to 0.10) 0 212.21 (236.60 to 12.17) 7/152/1 20.13 (20.36 to 0.10) 0 25.33 (211.56 to 0.90)
Circulating SHBG, nmol/l 10/233/1 20.10 (20.28 to 0.08) 0 22.19 (26.37 to 1.99) 17/459/3 20.06 (20.19 to 0.07) 0 20.87 (23.52 to 1.78)
Secondary outcomes
Circulating FSH, IU/l 7/73/0 20.45 (20.79 to 20.11) 0 20.52 (21.15 to 0.11) 23/601/4 20.08 (20.26 to 0.10) 59.3 21.29 (24.41 to 1.83)
Circulating LH, IU/l 7/73/0 20.34 (20.68 to 20.01) 0 21.26 (23.30 to 0.78) 13/382/2 0.01 (20.21 to 0.24) 58.1 0.27 (22.42 to 2.95)
Circulating progesterone,
nmol/l
9/199/0 0.03 (20.29 to 0.36) 44.0 21.20 (26.89 to 4.48) 0/0/0 — — —
Circulating E1S, nmol/l 3/44/0 0.09 (20.34 to 0.52) 0 0.49 (22.12 to 3.11) 6/125/2 20.03 (20.29 to 0.22) 0 20.03 (20.28 to 0.22)
Circulating free E2, pmol/L 3/145/0 20.09 (20.32 to 0.14) 0 20.71 (22.21 to 0.79) 3/77/0 0.07 (20.25 to 0.39) 0 0.18 (20.10 to 0.46)
Circulating T3, nmol/l 1/14/0 — 20.03 (20.11 to 0.05) 2/41/1 0.29 (20.14 to 0.72) 0 0.11 (20.03 to 0.26)
Circulating T4, nmol/l 1/14/0 — 21.60 (26.73 to 3.53) 3/59/1 0.31 (20.05 to 0.67) 0 3.53 (20.61 to 7.68)
Circulating TSH, mU/l 1/14/0 — 20.03 (20.86 to 0.80) 7/192/1 20.01 (20.21 to 0.19) 0 0.05 (20.26 to 0.35)
Circulating IGF-1, nmol/l 3/167/1 0.14 (20.07 to 0.35) 0 0.75 (20.60 to 2.11) 3/209/2 0.29 (20.39 to 0.97) 80.7 1.57 (21.75 to 4.89)
Urinary E2, nmol/24 h 1/11/3 — 21.81 (22.89 to 20.73) 1/18/0 — 0.05 (20.64 to 0.74)
Urinary E1, nmol/24 h 1/14/3 — 22.34 (24.80 to 0.12) 1/18/0 — 20.57 (21.68 to 0.54)
Menstrual cycle length, days 10/148/1 0 1.05 (0.13 to 1.97)
Luteal phase length, days 3/44/0 0 0.54 (20.32 to 1.40)
Follicular phase, days 7/92/0 7.6 0.81 (20.12 to 1.74)
SMD, standardized mean difference; MD, mean difference; I
2, I
2 test of heterogeneity; 95% CI, 95% conﬁdence interval; E1, estrone; E2, estradiol; E1S, estrone sulfate.
aNumber of participants in the control arms of all included studies combined.
bNumber of studies that have data available on this outcome, but where those data are not useable in meta-analysis.
cI
2 relates to the SMD except where no SMD data appear (in which case, it relates to MD).
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.ward conditions, the remainder in the community (three of these pro-
vided all food for the intervention period). Twenty-ﬁve studies were
carried out in North America, nine in Europe, ﬁve in Asia and four
each in Australia and South America.
Study quality varied, as shown in Supplemental data Table S1. All
but one of the included studies was randomized, and the non-
randomized study was a closely supervised metabolic crossover
study (Cassidy et al., 1995). Thirty-ﬁve studies masked participants
(4 did not and in 8 studies this was unclear) and 31 studies masked
outcome assessors (3 did not, 13 unclear). Twenty studies declared
a funding source with a commercial interest in the study results; 25
did not report industry funding; and 2 were unclear. Duration of inter-
vention was adequate in 42 studies, not in 5. Compliance was assessed
and reported in nine studies, partly done in 24, and not done in 14.
Isoﬂavone dose was well reported in 18 studies, partly in 27, and
not in 2. Isoﬂavones were analyzed in 17 studies, not in one study,
unclear in 29. Dropouts were fully reported in 25 studies, partly
reported in 20, not in 2. Ten studies were judged at low risk of bias.
Primary outcomes
Summary effect data are presented in Table I, with sensitivity analyses
omitting crossover study data unless t-test or exact P-values were
available in Table II. Summary forest plots (for outcomes with at
least four studies contributing data) are shown in Figs 2 (for premeno-
pausal women) and 3 (post-menopausal women).
Premenopausal women
Soy and isoﬂavone consumption had no effect on circulating total
estradiol, estrone or SHBG concentrations in premenopausal
women (on the basis of 6–11 studies per comparison, each compari-
son had over 200 women in combined control arms, combining with
either SMD or MD, no suggestion of heterogeneity). One further
study assessed the effect of soy isoﬂavones on circulating total
estrone and SHBG (data not useable in our meta-analysis), but
addition of these results would be unlikely to signiﬁcantly alter the
outcome. Using data only from the luteal phase (rather than the
point with the highest baseline measure) for total estradiol and
estrone resulted in no suggestions of an effect (circulating estradiol
SMD 0.03, 95% CI 20.17 to 0.23, I
2 0%; circulating estrone SMD
0.00, 95% CI 20.23 to 0.23, I
2 0%). Removing data for crossover
studies except where exact t-test or P-values were available resulted
in similar results to the main analysis, except that conﬁdence intervals
were generally widened slightly due to the loss of some power.
Post-menopausal women
In post-menopausal women, there was a small increase in circulating
total estradiol concentrations following soy isoﬂavone consumption,
but this was not statistically signiﬁcant (on the basis of 21 studies,
580 women in combined control groups, SMD 0.13, 95% CI 20.01
to 0.27, or an increase of 14%, 95% CI 21% to þ29%, P ¼ 0.07, I
2
29.3%), see Supplementary Fig. 1. Sensitivity analysis using MD was
not statistically signiﬁcant (MD 2.76 pmol/l, 95% CI 20.37 to 5.90),
nor was the sensitivity analysis removing studies not assessed as at
low risk of bias (SMD 0.17, 95% CI 20.07 to 0.41, eight studies,
231 in control groups, I
2 37.7%), or that removing the underpowered
crossover studies (SMD 0.15, 95% CI 20.02 to 0.32, P ¼ 0.09, I
2
39.2%). A funnel plot (Fig. 4) suggested that studies ﬁnding more
extreme increases and decreases of estradiol following soy isoﬂavone
intervention may be missing from the review. A further six studies
................................................................. ..............................................................
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Table II Sensitivity analysis of primary and secondary outcomes, removing crossover data except where exact t-test
statistic given
Premenopausal women Post-menopausal women
No. of studies/
participants
a
SMD (95% CI) No. of studies/
participants
a
SMD (95% CI)
Primary outcomes
Circulating total E2, pmol/l 4/347 20.08 (20.30 to 0.13) 17/940 0.15 (20.02 to 0.32)
Circulating total E1, pmol/l 4/347 20.09 (20.30 to 0.12) 4/150 20.14 (20.59 to 0.30)
Circulating SHBG, nmol/l 4/344 20.13 (20.34 to 0.09) 13/750 20.07 (20.22 to 0.09)
Secondary outcomes
Circulating FSH, IU/l 2/40 20.87 (21.72 to 20.02) 15/834 20.05 (20.32 to 0.22)
Circulating LH, IU/l 2/41 20.46 (21.16 to 0.25) 10/605 0.05 (20.25 to 0.34)
Circulating progesterone, nmol/l 2/219 0.14 (20.56 to 0.83) 0/0 —
Circulating E1S, nmol/l 1/29 MD: 1.88 (22.40 to 6.16) 2/77 0.12 (20.33 to 0.57)
Circulating free E2, pmol/l 3/284 20.09 (20.32 to 0.14) 2/85 0.15 (20.30 to 0.60)
Circulating T3, nmol/l 0/0 2/85 0.29 (20.14 to 0.72)
Circulating T4, nmol/l 0/0 2/85 0.29 (20.15 to 0.73)
Circulating TSH, mU/l 0/0 5/289 20.03 (20.26 to 0.20)
Circulating IGF-1, nmol/l 3/338 þ0.14 (20.07 to 0.35) 2/387 0.59 (0.38 to 0.79)
Menstrual cycle length, days 3/155 MD: 0.89 (20.61 to 2.39)
SMD, standardized mean difference; MD, mean difference; 95% CI, 95% conﬁdence interval; E1, estrone; E2, estradiol; E1S, estrone sulfate.
aNumber of participants in the intervention and control arms of all included studies combined.
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ﬂavones on total circulating estradiol in post-menopausal women, but
not presented the data in a useable way—addition of the results of
these studies could alter both the effect size and the statistical signiﬁ-
cance of the results of this meta-analysis.
Soy isoﬂavones had no effect on circulating total estrone (7 studies,
152 in control) or SHBG concentrations (17 studies, 459 women in
control groups), combining by either SMD or MD, with no suggestion
ofimportantheterogeneity.Therewereoneandthreestudies,respect-
ively, that clearly assessed estrone and SHBG in post-menopausal
women, but did not present data in a useable format—addition of
these studies would be unlikely to appreciably alter the results.
Subgrouping
Subgrouping by isoﬂavone source indicated that consumption of isoﬂa-
vone extracts (rather than soy foods or ISP) was associated with a sig-
niﬁcant increase in circulating estradiol among post-menopausal
women (Supplementary Fig. 1). The SMD of isoﬂavone extracts was
0.21 (95% CI 0.03 to 0.40, 14 studies, 398 in control groups, I
2
40.1%). However, given the total number of subgroups analyzed,
and the proximity of the conﬁdence interval for this subgroup to
zero, this ﬁnding may be due to chance alone.
Subgroupingbytotalisoﬂavonedoseorsoyproteinintakeresultedin
no suggestion of an effect moderated by either. It was not possible to
subgroup by equol-producer status (as not enough studies reported
data on equol concentrations) or by intensity of intervention (as all
studiesprovidedasupplementorfoodandnoneprovidedadvicealone).
Secondary outcomes
Premenopausal women
Soy isoﬂavones reduced circulating FSH and LH, and increased men-
strual cycle length in premenopausal women, as shown in Supplemen-
tary Figs 2–4. Effects on FSH and LH were observed in seven studies
(73 participants in control groups) and effects were statistically signiﬁ-
cant using SMD, but not MD. I
2 was 0%, suggesting no important het-
erogeneity between the studies. Removing studies not at low risk of
bias resulted in no remaining studies (trials were considered to be
at low risk of bias if participant and outcome assessor blinding were
all coded ‘yes’, industry funding was not reported, duration was
Figure 2 Effects of soy and isoﬂavones on circulating hormones and menstrual cycle length in premenopausal women (including all outcomes where
at least four studies contributed to the data). SMD analysis, all in units of standard deviation, except for menstrual cycle length, which is a MD analysis,
where the units are days.
Figure 3 Effects of soy and isoﬂavones on circulating hormones in post-menopausal women (presenting all outcomes where at least four studies
contribute to the data). SMD analysis, all in units of standard deviation.
428 Hooper et al.done and dropouts ‘done’, all other trials were considered at moder-
ate or high risk of bias—for further details, see deﬁnition below Sup-
plementary Table S1) whereas removing crossover studies without
exact t-test or P-values resulted in wider conﬁdence intervals, with
the effect on FSH remaining statistically signiﬁcant and loss of such sig-
niﬁcance for LH and menstrual cycle length.
Interpretation of SMD is problematic as it uses units of standard
deviation, but we can use the largest single study (Maskarinec 2002,
with 16 participants in the control group) to provide insight into the
magnitude of the effect using conventional units. In that study, the
control group FSH was 5.4 IU/l at the study end, so that the effect
of soy isoﬂavones on FSH corresponded to 21.2 IU/l (95% CI
20.3 to 22.2), a decrease of 22%. Control group LH concen-
trations at the study end were 4.5 IU/l, giving an effect size of
21.1 IU/l (95% CI 20.03 to 22.2), a decrease of 24%. All
studies that determined the effects of soy isoﬂavone intervention on
FSH or LH in premenopausal women were useable in meta-analysis.
Combined analysis of 10 studies (148 women in control groups)
suggested an increase in menstrual cycle length of 1.1 days with soy
isoﬂavones compared with control. Sensitivity analysis, removing
studies not at low risk of bias, removed statistical signiﬁcance
(WMD 1.21 days, 95% CI 20.98 to 3.41, two studies, 62 women
in control groups, I
2 28.3%).
Urinary estradiol concentrations were reduced in women taking soy
isoﬂavones, based on only one study of 14 women. Soy isoﬂavones
had no statistically signiﬁcant effects on progesterone, circulating free
estradiol or IGF-1 concentrations (where there were at least three
studies and at least 50 women in combined control groups). There
were insufﬁcient data to comment on the effects on circulating
estrone sulfate, T4,T 3, TSH, urinary estrone or urinary estradiol.
Using data only from the luteal phase (rather than the point with the
highest baseline measure) for circulating FSH and LH, and only from
the follicular phase for progesterone, resulted in no suggestions of
an effect (circulating FSH SMD 20.07, 95% CI 20.42 to 0.27, I
2
0%; circulating LH SMD 0.05, 95% CI 20.27 to 0.36, I
2 0%; circulating
progesterone SMD 20.02, 95% CI 20.30 to 0.26, I
2 17%).
Post-menopausal women
Soy isoﬂavone intake had no effect on FSH, LH, circulating estrone
sulfate, circulating free estradiol, TSH, T4 or IGF-1 concentrations
(where there were at least three studies and at least 50 women in com-
bined control groups). There were insufﬁcient data to comment on the
effects on progesterone, T3, urinary estrone or urinary estradiol.
Perimenopausal women
Two studies included some perimenopausal women, but only Alekel
2000 provided useable data for meta-analysis. Effects on circulating
estrone, circulating estradiol, FSH and IGF-1 were all non-signiﬁcant
(24 women in the control group).
Side effects
Gastrointestinal side effects, but not dropouts due to adverse effects
or any recorded side effect, were statistically signiﬁcantly more likely to
occur in participants taking any source of soy and/or isoﬂavones than
controls (pre- and post-menopausal women combined, gastrointesti-
nal side effects RR 1.8, 95% CI 1.3 to 2.6, eight studies, 507 in control
groups, I
2 0%; any side effect RR 1.9, 95% CI 0.5 to 8.0, two studies,
131 in control groups, I
2 79%; dropouts due to adverse events RR 1.6,
95% CI 0.7 to 3.7, four studies, 357 in control groups, I
2 25%).
Discussion
This systematic review of 47 studies assessed the effects of soy isoﬂa-
vones on hormone concentrations in pre- and post-menopausal
women. In premenopausal women, consumption of soy isoﬂavones
had no effect on circulating total estradiol, estrone or SHBG. There
weresigniﬁcantreductionsinFSH(by 22%,P ¼ 0.01)andLHconcen-
trations (by 24%, P ¼ 0.05), and an increase in menstrual cycle length
Figure 4 Funnel plot of results from included published studies on the effects of soy protein and isoﬂavones on circulating total estradiol (E2, pmol/
l) in post-menopausal women.
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2 0%, 10 studies with 148 women in
control groups) as shown in Table I and Fig. 3. However, these effects
should be considered tentative because in sensitivity analysis, when
only studies at low risk of bias were retained, the results were no
longer statistically signiﬁcant. No statistically signiﬁcant effects were
observed on free estradiol, progesterone or IGF-1 concentrations.
In post-menopausal women, there were no statistically signiﬁcant
effects of soy or isoﬂavones on circulating total estradiol, estrone or
SHBG, although there was a small non-signiﬁcant increase in total cir-
culating estradiol following soy (14%, P ¼ 0.07, 21 studies, 580
women analyzed in control groups). Soy had no effect on FSH, LH,
free estradiol or estrone sulfate, T4, IGF-1 or TSH.
These data are consistent with at most weak effects of soy isoﬂa-
vones on the hypothalamic–pituitary–gonadal axis in women. They
could occur via the effects of isoﬂavones on endogenous estrogen syn-
thesis, through alterations of enzymes involved in steroid metabolism,
including aromatase (Rice et al., 2006), 17b-hydroxysteroid dehydro-
genases, steroid sulfatases and sulfotransferases (Lacey et al., 2005).
Alternatively, isoﬂavones may exert estrogenic or anti-estrogenic
effects by binding to estrogen receptors, directly affecting transcription
of estrogen-regulated gene products (Kuiper et al., 1997; Kuiper et al.,
1998; Pike et al., 1999; Rosselli et al., 2000; An et al., 2001). Although
isoﬂavones have a weaker binding afﬁnity for estrogen receptors than
endogenous estrogens, circulating levels of isoﬂavones following con-
sumption of soy will exceed endogenous estrogen levels by several
orders of magnitude (Axelson et al., 1984; Cassidy et al., 1994; Adler-
creutz and Mazur, 1997). Our data, however, suggest no changes in
estrogen status in premenopausal women and borderline effects in
post-menopausal women. This lack of effect contrasts with notable
and often-cited animal data; for example, infertility in Western Austra-
lian sheep grazing on isoﬂavone-rich clover (Bennetts et al., 1946;
Adams, 1995) and captive North American cheetahs consuming
diets containing soy protein (Setchell et al., 1987). However, in both
cases, circulating levels of isoﬂavones were much higher than could
realistically be achieved in humans. In Australian sheep, this was
because of the high isoﬂavone exposure and in the cheetah, due to
their inability to glucuronidate isoﬂavones in vivo.
Whether the observed but tentative premenopausal changes in FSH
and LH reﬂect an estrogenic or anti-estrogenic effect is not clear.
These hormones were assessed in different studies at different
points in the menstrual cycle, including, for example, during the mid-
cycle gonadotrophin surge, when a decrease in LH is best construed
as an anti-estrogenic effect, while during the luteal phase a decrease
in LH may be an estrogenic effect. On the other hand, the increase
in menstrual cycle length suggests an anti-estrogenic effect, with
longer cycles linked to reduced breast cancer risk (Setchell et al.,
1984; Kelsey et al., 1993; Cassidy et al., 1994; Duncan et al., 1999a;
Messina et al., 2006a), and a growing body of evidence that increased
lifetime soy exposure lowers breast cancer risk (Wu et al., 2008).
In post-menopausal women, the small statistically non-signiﬁcant
increase in circulating estradiol concentrations is potentially of
concern, as a recent meta-analysis of nine prospective studies
showed that increased levels of circulating estradiol were associated
with an increased risk of breast cancer in post-menopausal women
(Endogenous Hormones and Breast Cancer Collaborative Group,
2002). Being in the top quintile of total estradiol, compared with the
bottom quintile, doubled breast cancer risk (RR 2.00, 95% CI 1.47 to
2.71). However it is difﬁcult to assess the absolute effect of the small
statistically non-signiﬁcant increase in circulating estradiol associated
withincreasedintakeofsoyfoodsandsupplementsobservedinoursys-
tematic review. In this regard, the fact that neither SHBG nor LH and
FSH concentrations were affected argues against a physiologically
important estrogenic effect. Furthermore, the available clinical and epi-
demiological data do not support the idea that soy isoﬂavone exposure
increases breast cancer risk (Messina et al., 2006a; Wu et al., 2008) or
menopausal symptoms (Nelson et al., 2006; Lethaby et al., 2007),
although there is conﬂicting and limited evidence that isoﬂavones
from red clover reduce hot ﬂush frequency in menopausal women
(Nelson et al., 2006; Coon et al., 2007).
There are many limitations of the data set used in this systematic
review and meta-analysis. The diversity of baseline and control
group values between studies for most hormones [also seen in pro-
spective studies (Endogenous Hormones and Breast Cancer Colla-
borative Group, 2002)] was managed by assuming that different
studies were effectively using different scales to measure these hor-
mones (e.g. variation in the methodology employed to assay a particu-
lar hormone may have generated consistent among-study variation in
hormone concentrations), and by carrying out meta-analysis using
SMD. Many data appeared to be skewed, so group means may be
dependent on a few extreme values and thus unreliable. Some
authors appropriately dealt with this by presenting their data as
medians or geometric means (only the latter being amenable to
meta-analysis). Other studies presented least squares means following
model adjustment, but these were not combinable in meta-analysis
due to associated smaller standard errors (so would have been
weighted incorrectly). Many parallel studies were small, with baseline
hormone levels that differed a great deal between the intervention and
the control groups (and where changes over time were smaller than
the initial difference between the groups, so that outcome data rep-
resented baseline levels more strongly than changes engendered by
time or the intervention). On the other hand, the crossover data
were underweighted in the analyses due to lack of information on
the within-participant differences in the studies. We checked that
these studies were not providing misleading data by running a sensi-
tivity analysis removing crossover studies without exact t-test or
P-values, and found that the effects were not greatly altered, but
that conﬁdence intervals were widened due to reduced power in
the remaining studies. Another issue was how to combine data
measured at different points during the menstrual cycle. Our decision
to take the point at which control data were greatest was not ideal,
but appeared the only realistic approach. Finally, a large number of
studies assessed the effects of soy isoﬂavones on at least one of the
selected outcomes, but did not report the data in a way that was
useable in meta-analysis. As far as possible, we collected details of
these missing data to document the extent of the problem.
To our knowledge, this is the ﬁrst systematic review and
meta-analysis to compare the endocrine effects of different soy pro-
ducts on hormonal status in women at different lifecycle stages. It pro-
vides weak evidence that soy and isoﬂavones decrease FSH and LH in
premenopausal women, and a suggestion that they may increase estra-
diol in post-menopausal women. The clinical implications of these rela-
tively modest hormonal changes are unclear and the clinical relevance
of these ﬁndings for women at different stages of the lifecycle require
conﬁrmation in further robust studies.
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Appendix: Characteristics of included studies
Study Participants Interventions Outcomes
Alekel 2000 Participants: peri-men (com) Design: parallel DO: 11, unclear from
which arms
USA (Alekel et al., 2000; Dent et al., 2001;
St Germain et al., 2001; Swain et al., 2002;
Moeller et al., 2003)
Analyzed: int 24, cont A 21,
cont B 24
Intervention: A: ISP versus milk protein Duration: 24 weeks
Med age: int 50, cont A 49,
cont B 51
B: ISP versus alcohol-washed ISP
Isoﬂav, mg/day: int 80, cont A unclear,
cont B 4.4 (AU)
Soy protein difference: 0 g/day
Arjmandi 2003 Participants: post-men (com) Design: parallel DO: int 16, cont 13
USA (Arjmandi et al., 2003, 2004) Analyzed: int 20, cont 22 Intervention: ISP versus milk protein Duration: 12 weeks
Mean age: int 62, cont 62 Isoﬂav, mg/day: int 88.4, cont 0 (AU)
Soy protein difference: 37 g/day
Arjmandi 2005 Participants: post-men (com) Design: parallel DO: int 13, cont 12
USA (Arjmandi et al., 2005) Analyzed: int 35, cont 27 Intervention: ISP versus no soy Duration: 52 weeks
Mean age: int 53, cont 56 Isoﬂav, mg/day: int 60, cont unclear (AU?)
Soy protein difference: 25 g/day
Aubertin-Leheudre 2007 Participants: obese post-men
(com)
Design: parallel DO: 14 in each arm
Canada (Aubertin-Leheudre et al., 2007) Analyzed: int 10, cont 10 Intervention: isoﬂav ext versus placebo Duration: 52 weeks
Mean age, sd: 58 overall Isoﬂav, mg/day: int 70, cont unclear (AU?)
Soy protein difference: 0 g/day
Baird 1995 Participants: post-men (com) Design: parallel DO: 6 (unclear from
which arms)
USA (Baird et al., 1995) Analyzed: int 66, cont 25 Intervention: whole soy versus usual diet Duration: 4 weeks
Mean age: unclear Isoﬂav, mg/day: int 165, cont unclear
(AU?)
Soy protein difference: unclear
Baum 1998 Participants: HC post-men
(com)
Design: parallel DO: 15 (unclear from
which arms)
USA (Baum et al., 1998; Persky et al., 2002;
Potter et al., 1998)
Analyzed: ISP90 21, ISP56 23,
cont 22
Intervention: ISP versus milk protein Duration: 24 weeks
Mean age: ISP90 61, ISP56 60,
cont 61
Isoﬂav, mg/day: ISP90 90, ISP56 56, cont
nil (AU)
Soy protein difference: 37 g/day
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Brink 2008 (NL, Italy, France) Participants: post-men (com) Design: parallel DO: int NL 5, It 13, Fr
14, cont NL 5, It 11, Fr
15
Netherlands, Italy, France (Brink et al., 2008) Analyzed: NL int 45, cont 46;
It int39,cont 39; Fr int34, cont
34
Intervention: isoﬂav ext versus nil Duration: 52 weeks
Mean age: NL int 53, cont 53;
It int53,cont 53; Fr int54, cont
54
Isoﬂav, mg/day: int 110, cont unclear
(AU)
Soy protein difference: 0 g/day
Brooks 2004 Participants: post-men (com) Design: parallel DO: int 2, cont 0
Canada (Lewis et al., 2006; Brooks et al., 2004) Analyzed: int 13, cont 15 Intervention: soy foods versus wheat
ﬂour
Duration: 16 weeks
Mean age: int 54, cont 53 Isoﬂav, mg/day: int 41.4, cont unclear
(AU?)
Soy protein difference: 8 g/day
Brown 2002 Participants: pre-men (com) Design: crossover DO: 12
USA (Brown et al., 2002) Analyzed: 14 Intervention ISP versus alternate foods Duration: 2 cycles
Mean age: 28 Isoﬂav, mg/day: int 40, cont none (AU?)
Soy protein difference: 31 g/day
Cassidy 1995 Participants: pre-men
(metabolic unit)
Design: crossover DO: 3 drop outs from
study 2
UK (Cassidy et al., 1994, 1995) Analyzed: Study 1: 6, Study 2:
6, Study 3: 5, Study 4: 6
Intervention: soy foods versus nil Duration: 1 cycle
Mean age: Study 1: 24, Studies
2–4: unclear
Isoﬂav, mg/day: Study 1: int 45, cont 1;
Study 2: int 25, cont unclear; Study 3:
unclear; Study 4: int 23, cont unclear (AU—
No)
Soy protein difference: Study 1 30 g/
day; Study 2 7 g/day; Study 3 unclear; Study
4 14 g/day
Cheng 2007 Participants: post-men (com) Design: parallel DO: 9 (unclear from
which arms)
Sweden (Cheng et al., 2007) Analyzed: int 26, cont 24 Intervention: isoﬂav ext versus oatmeal Duration: 12 weeks
Mean age: int 58, cont 56 Isoﬂav, mg/day: int 60, cont unclear (AU?)
Soy protein difference: 0 g/day
Cuevas 2003 Participants: raised LDL
post-men (com)
Design: crossover DO: unclear
Chile (Cuevas et al., 2003) Analyzed: 18 Intervention: ISP versus milk protein Duration: 4 weeks
Mean age: 59 Isoﬂav, mg/day: int 80, cont unclear (AU?)
Soy protein difference: 37 g/day
D’Anna 2007 Participants: post-men (com) Design: parallel DO: 48 int, 37 cont at
2 years
Italy (D’Anna et al., 2005; Atteritano et al., 2007;
Marini et al., 2007)
Analyzed: int 150, cont 154 Intervention: isoﬂav ext versus placebo Duration: 104 weeks
Mean age, sd: int 55, cont 54 Isoﬂav, mg/day: int 54, cont nil (AU)
Soy protein difference: 0 g/day
Dewell 2002 Participants: HC post-men
(com)
Design: parallel DO: 4 (unclear from
which arms)
USA (Dewell et al., 2002; Bruce et al., 2003) Analyzed: int 22, cont 16 Intervention: isoﬂav ext versus placebo Duration: 26 weeks
Mean age: int 69, cont 70 Isoﬂav, mg/day: int 90 AU, cont unclear
(AU)
Continued
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Soy protein difference: 0 g/day
Duncan 1999 Pre Participants: pre-men (com) Design: crossover DO: 6
USA (Xu et al., 1998; Duncan et al., 1999a;
Merz-Demlow et al., 2000; Wangen et al., 2000;
Phipps et al., 2001; Fritz et al., 2003)
Analyzed: 14 Intervention: ISP versus low isoﬂavone
ISP
Duration: 13 weeks
Mean age: 27 Isoﬂav, mg/day: highISO 128.7, medISO
64.7, Cont 10.0 (AU)
Soy protein difference: 0 g/day
Duncan 1999 Post Participants: post-men (com) Design: crossover DO: 4
USA (Duncan et al., 1999b; Xu et al., 2000;
Phipps et al., 2001; Wangen et al., 2001)
Analyzed: 18 Intervention: ISP versus low isoﬂavone
ISP
Duration: 13 weeks
Mean age: 57 Isoﬂav, mg/day: int 132, cont 7.1 (AU)
Soy protein difference: 0 g/day
Gann A 2005 Participants: pre-men (com) Design: parallel DO: unclear
USA (Gann et al., 2005) Analyzed: int 43, cont 43 Intervention: ISP versus low isoﬂavone
ISP
Duration: 3 cycles
Mean age: int 34, cont 33 Isoﬂav, mg/day: int 84.4, cont unclear
(AU)
Soy protein difference: 0 g/day
Gann B 2005 Participants: pre-men (com) Design: parallel DO: unclear
USA (Gann et al., 2005) Analyzed: int 38, cont 30 Intervention: ISP versus low isoﬂavone
ISP
Duration: 3 cycles
Mean age: int 34, cont 33 Isoﬂav, mg/day: int 84.4, cont unclear
(AU)
Soy protein difference: 0 g/day
Gardner 2001 Participants: HC post-men
(com)
Design: parallel DO: int 3, cont A 2,
cont B 1
USA (Gardner et al., 2001) Analyzed: int 31, cont A 30,
cont B 33
Intervention: ISP versus A milk protein, B
low isoﬂavone ISP
Duration: 12 weeks
Mean age: int 63, cont A 58,
cont B 58
Isoﬂav, mg/day: int 80, contA 2, contB 3
(AU)
Soy protein difference: 0 or 39 g/day
Garrido 2006 Participants: post-men (com) Design: parallel DO: none
Chile (Garrido et al., 2006) Analyzed: int 15, cont 14 Intervention: isoﬂav ext versus placebo Duration: 12 weeks
Mean age: int 54, cont 53 Isoﬂav, mg/day: int 100, cont unclear
(AU)
Soy protein difference: 0 g/day
Han 2002 Participants: post-men (com) Design: parallel DO: int 1, cont 1
Brazil (Han et al., 2002) Analyzed: int 40, cont 40 Intervention: isoﬂav ext versus glucose Duration: 16 weeks
Mean age: int 48, cont 49 Isoﬂav, mg/day: int 100, cont nil (AU)
Soy protein difference: 0 g/day
Harkness 2004 Participants: post-men (com) Design: crossover DO:1
USA (Harkness et al., 2004) Analyzed: 19 Intervention: isoﬂav ext versus placebo Duration: 26 weeks
Mean age: 71 Isoﬂav, mg/day: int 110, cont unclear (AU
- No)
Soy protein difference: 0 g/day
Huang 2006 Participants: post-men (com) Design: parallel DO: 1 overall (unclear
in which arm)
Taiwan (Huang et al., 2006) Analyzed: int IF200 15, int
IF100 15, cont 12
Intervention: isoﬂav ext versus nil Duration: 52 weeks
Continued
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Mean age: IF200 int 52, IF100
int 54, cont 51
Isoﬂav, mg/day: IF200 200, IF100 100,
cont nil (AU?)
Soy protein difference: 0 g/day
Jayagopal 2002 Participants: diabetic
post-men (com)
Design: crossover DO: 1
UK (Jayagopal et al., 2002) Analyzed: 32 Intervention: ISP versus microcrystalline
cellulose
Duration: 12 weeks
Mean age: 63 Isoﬂav, mg/day: int 132, contl unclear
(AU?)
Soy protein difference: 30 g/day
Knight 2001 Participants: post-men (com) Design: parallel DO: int 3, cont 1
Australia (Knight et al., 2001) Analyzed: int 9, cont 11 Intervention: ISP versus milk protein Duration: 12 weeks
Mean age: int 52, cont 54 Isoﬂav, mg/day: int 77.4, cont unclear
(AU)
Soy protein difference: 55 g/day
Kotsopoulos 2000 (PEARL) Participants: post-men (com) Design: parallel DO: int 20?, cont 35?
Australia (Kotsopoulos et al., 2000; Teede et al.,
2001, 2004, 2005; Dalais et al., 2003)
Analyzed: int 30, cont 20 Intervention: ISP versus milk protein Duration: 12 weeks
Mean age: int 60, cont 60 Isoﬂav, mg/day: int 118, cont unclear
(AU?)
Soy protein difference: 40 g/day
Kumar 2002 Participants: pre-men (com) Design: parallel DO: int 16, cont 15
USA (Kumar et al., 2002) Analyzed: int 33, cont 33 Intervention: ISP versus milk protein Duration: 3 cycles
Mean age: int 41, cont 43 Isoﬂav, mg/day: int 40 genistein, cont 0
(AU?)
Soy protein difference: unclear
Lichtenstein 2002 Participants: HC post-men
(com, AFP)
Design: crossover DO: 4 dropped out
but were replaced
USA (Lichtenstein et al., 2002; Desroches et al.,
2004; Wang et al., 2004; Goldin et al., 2005;
Vega-Lopez et al., 2005)
Analyzed: 10 or 11 Intervention: isoﬂav ext versus nil, also
ISP versus low isoﬂavone ISP
Duration: 6 weeks
Mean age: 64 Isoﬂav, mg/day: isoﬂav ext int 114, cont
nil, ISP int 102, cont 3 (AU)
Soy protein difference: g/day
Mackey 2000 Participants: HC post-men
(com?)
Design: parallel DO: 5 in total
(unclear in which
arms)
Australia (Eden et al., 2000; Mackey et al., 2000) Analyzed: int 25, cont 24 Intervention: ISP versus low isoﬂavone
ISP
Duration: 12 weeks
Mean age: int 56, cont 57 Isoﬂav, mg/day: int 65, cont ,4 (AU?)
Soy protein difference: 0 g/day
Martini OC 1999 Participants: pre-men (com) Design: crossover DO: 4
USA (Rutman et al., 1997; Martini et al., 1999) Analyzed: 16 Intervention: ISP versus milk protein Duration: 2 cycles
Mean age: 30 Isoﬂav, mg/day: int 38, cont unclear (AU?)
Soy protein difference: 20 g/day
Maskarinec 2002 Participants: pre-men (com) Design: parallel DO: 5 (unclear in
which arms)
USA (Maskarinec et al., 2002a, b, 2003) Analyzed: int 13, cont 16 Intervention: isoﬂav ext versus
maltodextrin
Duration: 52 weeks
Mean age: int 42, cont 43 Isoﬂav, mg/day: int 76, cont 0 (AU)
Soy protein difference: 0 g/day
Continued
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Maskarinec 2004 Participants: pre-men (com) Design: parallel DO: 17 int, 14 cont
USA (Maskarinec et al., 2004, 2005) Analyzed: int 92, cont 97 Intervention: soy foods versus usual diet Duration: 104 weeks
Mean age: int 43, cont 43 Isoﬂav, mg/day: int 57.1, cont 7.2 (AU)
Soy protein difference: 10–44 g/day
Murkies 1995 Participants: post-men (com) Design: parallel DO: int 5, cont 6
Australia (Murkies et al., 1995) Analyzed: int 24, cont 23 Intervention: soy foods versus
non-protein cont
Duration: 12 weeks
Mean age: int 54, cont 56 Isoﬂav, mg/day: unclear (AU?)
Soy protein difference: 18 g/day
Nagata 1998 Participants: pre-men, (com) Design: parallel DO: 0
Japan (Nagata et al., 1998; Takatsuka et al., 2000) Analyzed: int 31, cont 29 Intervention: soy foods versus usual diet Duration: 8 weeks
Mean age: int 26, cont 27 Isoﬂav, mg/day: int 71, cont unclear
(AU—No)
Soy protein difference: 12 g/day
Nahas 2004 Participants: post-men (com) Design: parallel DO: none
Brazil (Nahas et al., 2004) Analyzed: int 25, cont 25 Intervention: soy foods versus placebo Duration: 26 weeks
Mean age: int 54, cont 53 Isoﬂav, mg/day: int 60, cont unclear (AU?)
Soy protein difference: 1 g/day
Nettleton 2004 Participants: post-men (com) Design: crossover DO: 13
USA (Greany et al., 2004, 2008; Nettleton et al.,
2004, 2005a, b)
Analyzed: 20 HO br cancer,
20 without
Intervention: ISP versus milk protein Duration: 6 weeks
Mean age: hO br cancer 60,
without 56
Isoﬂav, mg/day: int 44.4, cont unclear
(AU)
Soy protein difference: 27 g/day
Nikander 2003 Participants: post-men HO br
cancer (com)
Design: crossover DO: 6
Finland(Nikanderetal.,2003a,b, 2004a,b, 2005;
Tormala et al., 2006)
Analyzed: 56 Intervention: isoﬂav ext versus placebo Duration: 12 weeks
Mean age: 54 Isoﬂav, mg/day: int 114, cont unclear
(AU)
Soy protein difference: 0 g/day
Scambia 2000 Participants: post-men (com) Design: parallel DO: unclear
Italy (Scambia et al., 2000) Analyzed: int 20, cont 19 Intervention: isoﬂav versus placebo Duration: 6 weeks
Mean age: int 54, cont 53 Isoﬂav, mg/day: int 50, cont unclear (AU?)
Soy protein difference: 0 g/day
Spence 2005 Participants: post-men (com,
AFP)
Design: crossover DO: 0
USA (Spence et al., 2005) Analyzed: 15 Intervention: ISP versus low isoﬂavone
ISP
Duration: 4 wks
Mean age: 58 Isoﬂav, mg/day: int 65, cont 3.1 (AU)
Soy protein difference: 0 g/day versus
ISP- or 40 g/day versus milk protein
Squadrito 2002 Participants: post-men (com) Design: parallel DO: 3 int, 4 cont
Italy (Squadrito et al., 2002, 2003; Crisafulli et al.,
2005; D’Anna et al., 2007)
Analyzed: int 27, cont 26 Intervention: isoﬂav ext (genistein) versus
placebo
Duration: 52 weeks
Mean age: int 56, cont 57 Isoﬂav, mg/day: int 54, cont unclear (AU?)
Soy protein difference: 0 g/day
Uesugi 2003 Participants: post-men (com) Design: parallel DO: int 0, cont 1
Japan (Uesugi et al., 2003) Analyzed: int 11, cont 10 Intervention: isoﬂav ext versus dextrin Duration: 12 weeks
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Mean age: int 55, cont 53 Isoﬂav, mg/day: int 61.8, cont unclear
(AU—No)
Soy protein difference: 0 g/day
Uesugi 2004 Participants: peri- and
post-men (com)
Design: crossover DO: unclear
Japan (Uesugi et al., 2004) Analyzed: 58 Intervention: isoﬂav ext versus placebo Duration: 4 wks
Mean age: 58 Isoﬂav, mg/day: int 42, cont unclear (AU)
Soy protein difference: 0 g/day
Upmalis 2000 Participants: post-men, (com) Design: parallel DO: 31 int, 24 cont
USA (Upmalis et al., 1999, 2000) Analyzed: int 59, cont 63 Intervention: isoﬂav versus placebo Duration: 12 weeks
Mean age: int 55, cont 54 Isoﬂav, mg/day: int 50, cont unclear (AU?)
Soy protein difference: 0 g/day
Woods 2000 Participants: post-men (com) Design: crossover DO: unclear
USA (Woods et al., 2000) Analyzed: 85 Intervention: isoﬂav ext versus placebo Duration: 12 weeks
Mean age: unclear Isoﬂav, mg/day: int 45, cont unclear (AU?)
Soy protein difference: unclear
Wu 2005 Participants: post-men, (com,
AFP)
Design: parallel DO: 6 (unclear from
which arms)
USA (Wu et al., 2005) Analyzed: int 17, cont 20 Intervention: soy food versus nil Duration: 8 weeks
Mean age: int 57, cont 60 Isoﬂav, mg/day: int 51, cont unclear (AU)
Soy protein difference: 15 g/day
Wu 2006 A and B Participants: post-men (com) Design: parallel DO: A int 8, cont 4, B
int 1, cont 7
Japan (Wu et al., 2006a, b) Analyzed: A: int 33, cont 33;
B: int 31, cont 31
Intervention: isoﬂav ext versus dextrin Duration: 52 weeks
Mean age: A: int 54, cont 55,
B: int 54, cont 55
Isoﬂav, mg/day: int 75, cont unclear (AU)
Soy protein difference: 0 g/day
Zitterman 2004 Participants: pre-men (com) Design: crossover DO: 3
Germany (Zittermann et al., 2004) Analyzed: 14 Intervention: soy foods versus nil Duration: 4 weeks
Mean age: 24 Isoﬂav, mg/day: int 52, cont ,0.1 (AU)
Soy protein difference: 22 g/day
ISP, isolated soy protein; AU, aglycone units; Cont, control group; Int, intervention group; Com, community; Isoﬂav, isoﬂavone/s; FP, food provided; DO, dropouts; HC,
hypercholesterolaemic; Br cancer, breast cancer; HO, history of; AFP, all food provided.
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